- Recordati’s 1Q revenue for 2024 has beaten estimates by reaching €607.8 million, significantly higher than the estimated €584.3 million.
- The complete financial results for this quarter will be made public on May 9, 2024.
- Compared to Q1 of 2023, the revenue for the same time period in 2024 has increased by 10.2% or even 10.9% if the revenue generated from Avodart®/Combodart® (€27.5m) is excluded.
- This excellent performance at the beginning of the year was experienced by both business entities and the international and Türkiye phasing patterns were similar to those of Q1 2023.
- Despite the negative impact of currency exchange of €31.2m (mostly on Türkish Lira, offset by price inflation) was felt during Q1, the company managed to overcome this setback.
- Regarding the share rating, 4 are recommending to buy, 7 vouch for hold and 1 suggests sellingRecordati shares.
A look at Recordati SpA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Recordati SpA, a pharmaceutical company, holds promising long-term prospects according to Smartkarma Smart Scores analysis. With a solid score in Value and respectable ratings in Dividend, Growth, Resilience, and Momentum, the company appears to be positioned well in various key areas. This suggests a positive outlook for Recordati SpA in the long run, supported by its strong performance across multiple critical factors.
Recordati SpA, known for manufacturing pharmaceuticals worldwide, has received encouraging Smart Scores across key indicators. The company’s competitive positioning in terms of Dividend, Growth, Resilience, and Momentum, complemented by a fair Value score, underlines its potential for sustained growth and stability. Investors may find Recordati SpA a compelling investment option based on its overall positive assessment across these key factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
